PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|June 8, 2026
Innovative Screening Strategies for Cyclodextrin Interactions: AI, Computational Models, and Experimental Approaches
Author(s)Ligand
Poor solubility remains one of the most persistent and costly challenges in pharmaceutical drug development. Inside this eBook you'll find peer-reviewed research and expert perspectives on how AI, machine learning, and molecular dynamics simulations are transforming cyclodextrin-based drug formulation. From a novel nomenclature system that enables AI-driven structural optimization to a landmark case study examining remdesivir's interactions with sulfobutylether-β-cyclodextrins, readers will gain actionable insight into predictive modeling strategies that reduce API waste, accelerate development timelines, and improve the odds of getting complex small molecules to patients.
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.